Cellectar Biosciences reports Q2 financial results, conference call on August 14.
ByAinvest
Thursday, Aug 7, 2025 8:21 am ET1min read
CLRB--
Cellectar Biosciences focuses on the discovery, development, and commercialization of drugs for cancer treatment. The company's proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform aims to develop the next generation of cancer cell-targeting treatments, delivering improved efficacy and better safety by minimizing off-target effects. Cellectar's product pipeline includes iopofosine I 131, CLR 121225, and CLR 121125, among others [1].
Investors and financial professionals are encouraged to participate in the conference call and webcast to gain insights into Cellectar's financial performance and corporate update. For more information, please visit Cellectar's Investor Relations website.
References:
[1] https://www.stocktitan.net/news/CLRB/cellectar-biosciences-to-report-second-quarter-financial-results-and-la636yqfo3tb.html
• Cellectar Biosciences to report Q2 2025 results on August 14, 2025. • Conference call at 8:30am Eastern Time. • Toll-free number: 1-800-717-1738. • Conference ID: 94699. • Webcast available on the company's Investor Relations website.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company, has scheduled its second quarter 2025 financial results announcement and corporate update for August 14, 2025, at 8:30 AM ET. The company will host a conference call accessible via toll-free number 1-800-717-1738 (Conference ID: 94699) and webcast. A replay of the presentation will be available in the Events section of Cellectar's Investor Relations website [1].Cellectar Biosciences focuses on the discovery, development, and commercialization of drugs for cancer treatment. The company's proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform aims to develop the next generation of cancer cell-targeting treatments, delivering improved efficacy and better safety by minimizing off-target effects. Cellectar's product pipeline includes iopofosine I 131, CLR 121225, and CLR 121125, among others [1].
Investors and financial professionals are encouraged to participate in the conference call and webcast to gain insights into Cellectar's financial performance and corporate update. For more information, please visit Cellectar's Investor Relations website.
References:
[1] https://www.stocktitan.net/news/CLRB/cellectar-biosciences-to-report-second-quarter-financial-results-and-la636yqfo3tb.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet